Home » Stocks » ALNY

Alnylam Pharmaceuticals, Inc. (ALNY)

Stock Price: $144.87 USD -6.72 (-4.43%)
Updated Feb 25, 2021 1:36 PM EST - Market open
Market Cap 17.74B
Revenue (ttm) 492.85M
Net Income (ttm) -858.28M
Shares Out 114.99M
EPS (ttm) -7.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $144.87
Previous Close $151.59
Change ($) -6.72
Change (%) -4.43%
Day's Open 151.92
Day's Range 143.43 - 154.80
Day's Volume 234,604
52-Week Range 84.97 - 178.41

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
24/7 Wall Street - 3 days ago

With the trading day more than halfway over, the broad markets could not make up their mind on a direction.

Other stocks mentioned: FL, NVDA, PBR, PBR.A, DAL, BBIO, FREE, MAR, PZZA, UAL
Business Wire - 6 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 1...

Zacks Investment Research - 1 week ago

Alnylam (ALNY) reported a wider-than-expected loss but revenues beat estimates in the fourth quarter of 2020.

Zacks Investment Research - 2 weeks ago

Alnylam (ALNY) delivered earnings and revenue surprises of -8.29% and 14.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 weeks ago

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 19.19% over the past year to ($1.60), which...

Business Wire - 2 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter...

Business Wire - 4 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth qua...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year strategy “Alnylam P5x25” focused on the C...

Seeking Alpha - 1 month ago

Alnylam announced that the HELIOS-A Phase III study of vutrisiran for hATTR-polyneuropathy achieved all of its primary and secondary endpoints. Vutrisiran's improved dosing profile and tolerab...

Zacks Investment Research - 1 month ago

Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an invest...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 3...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of Tolga Tanguler to the role of Chief C...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is kicking off a virtual R&D Day event today. During the two-day event, ...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event ...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published two new reports: the second annual update on its Patient...

Zacks Investment Research - 2 months ago

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 2 months ago

Alnylam (ALNY) completes enrollment in its phase III study of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLU...

The Motley Fool - 2 months ago

The company's rare disease treatments are a huge success and there will probably be a lot more of them.

The Motley Fool - 2 months ago

The company's rare disease treatments are a huge success and there will probably be a lot more of them.

Seeking Alpha - 2 months ago

Revenue is growing at a high percentage rate, but on a small base. Heavy investment in R&D will pay off as the decade progresses.

Zacks Investment Research - 3 months ago

The FDA approves Alnylam's (ALNY) Oxlumo injection for subcutaneous use, to lower urinary oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 4...

Benzinga - 3 months ago

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluri...

Other stocks mentioned: ADXS, ARWR
Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a new framework for value-based agreements (VBAs) design...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved...

Zacks Investment Research - 3 months ago

Alnylam (ALNY) gets European approval for Oxlumo (lumasiran) for the treatment of primary hyperoxaluria type 1 in all age groups.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the European Commission (EC) has granted marketing ...

Seeking Alpha - 3 months ago

Alnylam exceeded third-quarter sales expectations, with a stronger-than-expected recovery in Onpattro and healthy Givlaari sales. Another look at the Phase I ALN-AGT study showed double-digit ...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive interim data from the ongoing Phase 1 study of ...

Zacks Investment Research - 3 months ago

Alnylam (ALNY) reports a wider-than-expected loss, while sales beat estimates in the third quarter of 2020.

Seeking Alpha - 3 months ago

Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q3 2020 Results - Earnings Call Transcript

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ...

Zacks Investment Research - 3 months ago

Alnylam (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the fo...

Zacks Investment Research - 3 months ago

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Other stocks mentioned: ACAD, AVRO, BHVN, BNTX
Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has won the 2020 Prix Galien USA Award for Best Biote...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that, for the second year in a row, Science magazine has...

Zacks Investment Research - 3 months ago

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quar...

Zacks Investment Research - 4 months ago

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of th...

Zacks Investment Research - 4 months ago

Alnylam (ALNY) gets positive opinion from the CHMP for lumasiran for the treatment of primary hyperoxaluria type 1.

The Motley Fool - 4 months ago

Two small biotechs collaborated to find a coronavirus vaccine, but one of them may come out way ahead due to its expertise and other partnerships.

Other stocks mentioned: BIIB, GSK, VIR
Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use ...

Zacks Investment Research - 4 months ago

Alnylam (ALNY) releases positive top-line data from the ILLUMINATE-B pediatric phase III study of lumasiran, in development for the treatment of PH1.

Seeking Alpha - 4 months ago

Alnylam's announcement on ILLUMINATE-B was light on details, but management talked about "clinically significant" efficacy in young pediatric patients with PH1 and a clean safety profile.

Investors Business Daily - 4 months ago

Alnylam Pharmaceuticals reported positive results from a clinical trial in patients under age six for its RNAi therapy to treat a rare, possibly fatal disease, but ALNY stock slipped early. Th...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-B pediatric...

About ALNY

Alnylam Pharmaceuticals, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of ad... [Read more...]

Industry
Biotechnology
IPO Date
May 28, 2004
CEO
John Maraganore
Employees
1,453
Stock Exchange
NASDAQ
Ticker Symbol
ALNY
Full Company Profile

Financial Performance

In 2020, ALNY's revenue was $492.85 million, an increase of 124.28% compared to the previous year's $219.75 million. Losses were -$858.28 million, -3.14% less than in 2019.

Financial Statements

Analyst Forecasts

According to 24 analysts, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is 174.09, which is an increase of 20.17% from the latest price.

Price Target
$174.09
(20.17% upside)
Analyst Consensus: Buy